Kidney transplantation has become the treatment of choice for patients with end-stage renal
disease because of better surgical techniques and the availability of more powerful …

The safety and efficacy of tacrolimus (Prograf) in renal transplantation is well established.
Achieving longterm patient and graft survival are the ultimate goals following transplantation …

INTRODUCTION: The 1-year results of the phase III US Multicenter Trial comparing
tacrolimus-and cyclosporine (Sandimmun)-based immunosuppressive therapy in kidney …

On April 22, 1997, the Food and Drug Administration (FDA) approved Prograf (tacrolimus,
Fujisawa, Inc., Deerfield, IL) for use in the prevention of graft rejection in kidney …

Tacrolimus has significantly improved outcomes for kidney transplant patients and remains
the cornerstone of immunosuppressive therapy. While improvements in short-term outcomes …

Achieving long-term graft survival and optimal patient health are ultimate clinical goals in
renal transplantation. Many factors negatively impact long-term transplant outcomes …

Tacrolimus is a cornerstone immunosuppressive agent in renal transplantation and
compared with ciclosporin, its use is associated with a reduced incidence of acute rejection …

To improve long-term outcome after renal transplantation, attention should be placed on the
tailored use of immunosuppressive regimens that have a more favorable impact on the …

The optimal long-term regimen for immunosuppression for kidney transplant recipients is
unknown. We conducted a randomized trial involving 150 kidney transplant recipients to …

Objective: To compare tacrolimus with cyclosporin for immunosuppression in renal
transplantation. Design: Meta-analysis of randomised trials of two treatments after kidney …